Richard Jaffe, MD
Psychiatry · Philadelphia, PANPI 1962448167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,588 of the $100,982 with a category attached, or 89.7%. 8 manufacturers reported payments, led by Alkermes, Inc. at 42.8% of the total. Reporting peaked in 2019 at $33,759 and has fallen 99.8% since, to $57 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $726.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$43K
- AbbVie$30K
- Teva Pharmaceuticals USA, Inc.$24K
- Otsuka America Pharmaceutical, Inc.$4K
- Sunovion Pharmaceuticals Inc.$90
- Johnson & Johnson$59
- plus $58 from 2 others
What the payments were for
- Speaking & faculty fees$90,58890%
- Travel & lodging$7,1887%
- Food & beverage$3,2063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 48 | $43,263 |
| AbbVie(2 entities) | 36 | $29,979 |
| Teva Pharmaceuticals USA, Inc. | 34 | $23,867 |
| Otsuka America Pharmaceutical, Inc. | 10 | $3,666 |
| Sunovion Pharmaceuticals Inc. | 6 | $90 |
| Johnson & Johnson | 2 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$138,602
- ARISTADA INITIO$34,651
- LYBALVI$31,517
- VRAYLAR$29,781
- UZEDY$17,796
- AUSTEDO$3,871
- ABILIFY MAINTENA$3,448
How this compares
$100,982 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 77 | $4,738 |
| Duloxetine Hcl | 49 | $3,382 |
| Vilazodone Hcl | 17 | $2,186 |
| Atomoxetine Hcl | 16 | $1,450 |
| Bupropion XlBupropion Hcl | 48 | $1,367 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 97 | $1,027 |
| Clonazepam | 81 | $987 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $780 |
| Buspirone Hcl | 90 | $739 |
| Mirtazapine | 53 | $654 |
| Lamotrigine | 54 | $606 |
| Escitalopram Oxalate | 49 | $528 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $460 |
| Quetiapine Fumarate | 32 | $427 |
| Methylphenidate Hcl | 21 | $377 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.